Detalhe da pesquisa
1.
HDL-apoA-I kinetics in response to 16 wk of exercise training in men with nonalcoholic fatty liver disease.
Am J Physiol Endocrinol Metab
; 318(6): E839-E847, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286882
2.
Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise.
J Clin Endocrinol Metab
; 108(4): 888-896, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36274035
3.
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
Diabetes Care
; 45(6): 1408-1415, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35312749
4.
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
Diabetes Care
; 43(9): 2128-2136, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641376
5.
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.
Diabetes Care
; 44(3): e61, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33608329